NuCana (NCNA) Depreciation & Amortization (CF) (2017 - 2025)
NuCana's (NCNA) quarterly Depreciation & Amortization (CF) came in at $91781.5 in Q4 2025, down 37.82% year-on-year from $147602.7 in Q4 2024, and down 1.42% quarter-over-quarter from $93106.0 in Q3 2025.
NuCana (NCNA) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
NuCana has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $91781.5 for Q4 2025.
- Depreciation & Amortization (CF) for Q4 2025 came in at $91781.5, down 37.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $184887.5 (down 72.29% YoY), and the FY2025 annual result was $361271.8, down 45.86% from the prior year.
- Depreciation & Amortization (CF) came in at $91781.5 for Q4 2025 at NuCana, down from $93106.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $362614.9 in Q4 2021 to a low of $91781.5 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $178426.6 (2023), against an average of $216883.8.
- Across the five-year window, Depreciation & Amortization (CF) advanced 23.15% in 2021 and plunged 47.22% in 2023, its largest moves.
- NuCana's Depreciation & Amortization (CF) stood at $362614.9 in 2021, then decreased by 5.19% to $343792.8 in 2022, then slumped by 49.1% to $175002.4 in 2023, then retreated by 15.66% to $147602.7 in 2024, then plunged by 37.82% to $91781.5 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $91781.5 (Q4 2025), $93106.0 (Q3 2025), and $147602.7 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 91,781.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 91,781.47 |
| Dec 31, 2025 | 91,781.47 |
| Sep 30, 2025 | 93,105.99 |
| Sep 30, 2025 | 93,105.99 |
| Dec 31, 2024 | 147,602.71 |
| Dec 31, 2024 | 147,602.71 |
| Sep 30, 2024 | 175,405.52 |
| Sep 30, 2024 | 175,405.52 |
| Jun 30, 2024 | 171,662.02 |
| Jun 30, 2024 | 171,662.02 |
| Mar 31, 2024 | 172,518.47 |
| Mar 31, 2024 | 172,518.47 |
| Dec 31, 2023 | 175,002.42 |
| Dec 31, 2023 | 175,002.42 |
| Sep 30, 2023 | 184,935.98 |
| Sep 30, 2023 | 184,935.98 |
| Jun 30, 2023 | 181,447.66 |
| Jun 30, 2023 | 181,447.66 |
| Mar 31, 2023 | 173,817.86 |
| Mar 31, 2023 | 173,817.86 |